The most common side effects of INVEGA HAFYERA® include: injection site reactions, weight gain, headache, upper respiratory ...

Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...

AbbVie stock drops after Phase 2 trials of emraclidine fail to meet primary endpoint. The company continues data analysis for ...

“The journey through these phases varies for each person and may cycle, depending on the response to treatment and external stressors,” says Michael Kane, MD, a psychiatrist and the chief ...

For patients with schizophrenia, repetitive transcranial magnetic stimulation (rTMS) was effective and safe in treating ...

New research highlights neuroglia (or glia cells) as critical players in mental health, potentially influencing conditions like depression and schizophrenia.

Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

Researchers have identified a potential diagnostic tool for schizophrenia by measuring brain cell activity between the ...

ED visits related to hallucinogen use are linked to a 21-fold increased risk of schizophrenia spectrum disorder, results of a ...

AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock ...

Researchers conducted a cohort study to assess the predictive value of plasma MMP9 in antipsychotic treatment response among patients with schizophrenia.

Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two ...